Puma Biotechnology, Inc. (Nasdaq: PBYI) recently announced stock awards for four newly hired non-executive employees. The company’s compensation committee approved the grants, covering a total of 25,750 shares of Puma common stock.
The awards were made under Puma‘s 2017 Employment Inducement Incentive Award Plan. This plan allows for equity awards to incentivize new hires. The stock options vest over three years, with one-third vesting after one year and the remainder vesting in six-month increments thereafter. Continued employment is a condition for vesting.
These awards are considered material inducements for the new employees joining Puma, thus complying with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology is a biopharmaceutical company focused on developing and marketing cancer treatments. The company holds global rights to NERLYNX® (neratinib), approved by the U.S. Food and Drug Administration for treating certain types of breast cancer. The drug is used in both adjuvant and metastatic settings. NERLYNX also holds marketing authorization from the European Commission.
In addition to NERLYNX, Puma is developing alisertib, an anti-cancer drug. The company has initiated Phase II clinical trials for alisertib in the treatment of small cell lung cancer and breast cancer. These trials, ALISCA™-Lung1 and ALISCA™-Breast1, respectively, represent significant steps in Puma‘s broader research and development efforts.
The company’s focus remains on developing innovative therapies to improve cancer care. The recent stock grants are intended to attract and retain top talent to support these ongoing initiatives. Further details on the company’s financial performance and pipeline can be found in its public filings.
Related
